Plymouth, Minnesota-based Peytant designed its AMStent to treat pulmonary obstructions caused by cancer. The novel, proprietary therapy platform is indicated for treating tracheobronchial strictures produced by malignant neoplasms in adult patients.

The company developed AMStent as the first product offering within its amnion-based covered stent platform. It combines a minimally invasive catheter delivery system with a stent covered in material created from amnion.